protoporphyrin ix has been researched along with Neoplasms in 83 studies
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human tumor cells of the lines WiDr (adenocarcinoma of the rectosigmoid colon), NHIK 3025 (carcinoma of the cervix), and V79 Chinese hamster fibroblasts were treated with 5-aminolevulinic acid (ALA) and ALA esterified to C1-C3 and C6-C8 chained aliphatic alcohols (ALA-esters)." | 3.69 | Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. ( Anholt, H; Berg, K; Gaullier, JM; Ma, LW; Moan, J; Peng, Q; Selbo, PK, 1997) |
| "A better understanding of why cancer cells fluoresce with 5-ALA would improve its use in cancer diagnostics and therapies." | 2.61 | In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? ( Gleadle, JM; MacGregor, MN; McNicholas, K, 2019) |
| "5-Aminolevulinic acid (5-ALA) is a naturally occurring amino acid and precursor of heme and protoporphyrin IX (PpIX)." | 2.53 | 5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction. ( Fujino, M; Ito, H; Li, XK; Nishio, Y; Tanaka, T, 2016) |
| "For example, breast cancer COH-BR1 and prostate cancer PC3 cells exhibited a rapid and prolonged upregulation of inducible nitric oxide synthase (iNOS) after sensitization with 5- aminolevulinic acid (ALA)-induced protoporphyrin-IX, followed by broad-band visible irradiation." | 2.53 | Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy. ( Fahey, JM; Girotti, AW; Korytowski, W, 2016) |
| "Because tumors and other proliferating cells tend to exhibit a higher level of PpIX than normal cells after ALA incubation, ALA has been used as a prodrug to enable PpIX fluorescence detection and photodynamic therapy (PDT) of lesion tissues." | 2.52 | Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement. ( Chen, B; Kraus, D; Palasuberniam, P; Yang, X, 2015) |
| "Elucidation of the mechanisms of cancer cell elimination by PDT might help in establishing highly specific, non-genotoxic anti-cancer treatment of tomorrow." | 2.44 | The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances. ( Bielawski, KP; Grulkowski, I; Krachulec, J; Selivanova, G; Zawacka-Pankau, J, 2008) |
| "Photodynamic therapy (PDT) for cancer patients has developed into an important new clinical treatment modality in the past 25-years." | 2.40 | 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. ( Berg, K; Giercksky, KE; Kongshaug, M; Moan, J; Nesland, JM; Peng, Q; Warloe, T, 1997) |
| "Recent studies showed that a novel anti-cancer drug, Alectinib, an orally available, highly selective, potent second-generation inhibitor of anaplastic lymphoma tyrosinkinase binds to ferrochelatase." | 1.62 | Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin. ( Essmann, F; Gillissen, B; Kemmner, W; Richter, A, 2021) |
| "We established a malignancy model by gradually increasing the cell density of cancer cells." | 1.62 | Efficiency of aminolevulinic acid (ALA)-photodynamic therapy based on ALA uptake transporters in a cell density-dependent malignancy model. ( Lai, HW; Nakajima, M; Ogura, SI; Takahashi, K; Tanaka, T, 2021) |
| "In mice with intradermal tumors that were orally administered ALA (200 mg/kg daily for 5 days), the tumor in each mouse was simultaneously irradiated (8 h/day for 5 days) using a wirelessly powered implantable green LED device (532 nm, 0." | 1.56 | Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid. ( Fujie, T; Fujita, K; Kirino, I; Morimoto, Y; Sakanoue, K; Sugita, R; Takeoka, S; Uemoto, S; Yamagishi, K, 2020) |
| "Cancer cells and mice models of cancer were treated with 5-ALA-PDT, MEK inhibitor or both MEK inhibitor and 5-ALA-PDT, and treatment efficacies were evaluated." | 1.51 | Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy. ( Chelakkot, VS; Hirasawa, K; Rice, CP; Rutihinda, SG; Som, J; Yoshioka, E, 2019) |
| "Photodynamic therapy is a promising cancer therapy modality but its application for deep-seated tumor is mainly hindered by the shallow penetration of visible light." | 1.48 | Development of a functionalized UV-emitting nanocomposite for the treatment of cancer using indirect photodynamic therapy. ( Arellano, DL; Chauhan, K; Fournier, PGJ; Hirata, GA; Jain, A; Juárez, P; Sengar, P; Verdugo-Meza, A, 2018) |
| "Here, we developed a cancer-cell specific photosensitizer nano-delivery system by synthesizing protoporphyrin IX (PpIX)-conjugated pullulan (P) with reducible disulfide bonds." | 1.46 | Specific light-up pullulan-based nanoparticles with reduction-triggered emission and activatable photoactivity for the imaging and photodynamic killing of cancer cells. ( Bao, Y; Li, Y; Qian, M; Wang, J; Xia, J; Zhang, L, 2017) |
| " However, chemical instability, low bioavailability and poor pharmacokinetic profile limit systemic efficacy of 5-ALA." | 1.46 | Activity of phosphatase-sensitive 5-aminolevulinic acid prodrugs in cancer cell lines. ( Allémann, E; Babič, A; Herceg, V; Lange, N, 2017) |
| " eEF1A1 was found to enrich ALA-induced PpIX in cells by competitively blocking the downstream bioavailability of PpIX." | 1.43 | eEF1A1 binds and enriches protoporphyrin IX in cancer cells in 5-aminolevulinic acid based photodynamic therapy. ( Cui, X; Fan, Z; He, H; Li, B; Liu, W; Wei, D; Wei, X; Ye, H; Zhu, N, 2016) |
| "(11)C-MALA in tumors was continuously decreased thereafter, and the elimination rate of (11)C-MALA from AsPC-1 tumors with the highest ALAD expression level was slower than from other tumors with lower expression levels." | 1.40 | Preclinical characterization of 5-amino-4-oxo-[6-11C]hexanoic acid as an imaging probe to estimate protoporphyrin IX accumulation induced by exogenous aminolevulinic acid. ( Arano, Y; Kato, K; Kikuchi, T; Okada, M; Saga, T; Sudo, H; Sugyo, A; Suzuki, C; Tsuji, AB; Zhang, MR, 2014) |
| "Amongst all the different treatments of cancer such as surgery, chemotherapy and radiation therapy, surgical resection is the most effective." | 1.40 | Multi-channel LED light source for fluorescent agent aided minimally invasive surgery. ( Durfee, R; Kairdolf, B; Ren, J; Venugopalan, J; Wang, MD; Xu, J, 2014) |
| "In subcutaneous A431 tumors in mice, pretreatment with Vit D induced the expression of C/EBPβ isoforms, and of coproporphyrinogen oxidase (CPO), a heme pathway enzyme responsible for the conversion of 5-aminolevulinic acid (ALA) into protoporphyrin IX (PpIX), the principal light-absorbing molecule during PDT." | 1.39 | Mechanism of differentiation-enhanced photodynamic therapy for cancer: upregulation of coproporphyrinogen oxidase by C/EBP transcription factors. ( Anand, S; Hasan, T; Maytin, EV, 2013) |
| "Higher ALA-induced PpIX fluorescence in cancer cell lines as compared to normal ones was not detected by all the methods used." | 1.39 | Factors implicated in the assessment of aminolevulinic acid-induced protoporphyrin IX fluorescence. ( Cunderlíková, B; Mateasík, A; Peng, Q, 2013) |
| "Protoporphyrin IX is an important kind of organic compound for vital movement, and can be used as the sign of tumour blood." | 1.34 | [Fluorescence spectrum analysis system for protoporphyrin IX in serum based on wavelet transform]. ( Liu, Y; Lu, J; Luo, XS; Ni, XW; Shen, ZH; Yang, HP; Zhu, DM, 2007) |
| " It allows quasiquantitative testing of different protoporphyrin IX precursors with respect to dose-response curves and pharmacokinetics, as well as the evaluation of different incubation conditions and/or different drug formulations." | 1.31 | Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia. ( Etter, AL; Gerber, P; Jichlinski, P; Kucera, P; Lange, N; Marti, A; van Den Bergh, H; Vaucher, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.20) | 18.7374 |
| 1990's | 4 (4.82) | 18.2507 |
| 2000's | 16 (19.28) | 29.6817 |
| 2010's | 44 (53.01) | 24.3611 |
| 2020's | 18 (21.69) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 2 |
| Hitosugi, T | 1 |
| Zhang, L | 2 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 3 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 2 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 2 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 2 |
| Gillissen, B | 1 |
| Richter, A | 1 |
| Essmann, F | 1 |
| Kemmner, W | 1 |
| Chen, A | 1 |
| Yang, F | 1 |
| Kuang, J | 1 |
| Xiong, Y | 1 |
| Mi, BB | 1 |
| Zhou, Y | 1 |
| Hu, JJ | 1 |
| Song, SJ | 1 |
| Wan, T | 1 |
| Wan, ZZ | 1 |
| Huang, HY | 1 |
| Li, XR | 1 |
| Song, W | 1 |
| Qiu, WX | 2 |
| Kiening, M | 1 |
| Lange, N | 4 |
| Pétusseau, A | 1 |
| Bruza, P | 1 |
| Pogue, B | 1 |
| Xu, X | 2 |
| Wang, C | 1 |
| Guan, W | 1 |
| Wang, F | 1 |
| Li, X | 1 |
| Yuan, J | 1 |
| Xu, G | 1 |
| Ogbonna, SJ | 2 |
| York, WY | 1 |
| Nishimura, T | 1 |
| Hazama, H | 4 |
| Fukuhara, H | 1 |
| Inoue, K | 2 |
| Awazu, K | 4 |
| Zhang, XQ | 1 |
| Cai, SS | 1 |
| He, YM | 1 |
| Zhang, M | 1 |
| Cao, J | 1 |
| Mei, H | 1 |
| Li, S | 1 |
| He, B | 1 |
| Li, K | 1 |
| Dong, W | 1 |
| Qiu, L | 1 |
| Liu, Q | 1 |
| Lv, G | 1 |
| Peng, Y | 1 |
| Xie, M | 1 |
| Lin, J | 1 |
| McNicholas, K | 1 |
| MacGregor, MN | 1 |
| Gleadle, JM | 1 |
| Grigalavicius, M | 1 |
| Mastrangelopoulou, M | 1 |
| Berg, K | 4 |
| Arous, D | 1 |
| Ménard, M | 1 |
| Raabe-Henriksen, T | 1 |
| Brondz, E | 1 |
| Siem, S | 1 |
| Görgen, A | 1 |
| Edin, NFJ | 1 |
| Malinen, E | 1 |
| Theodossiou, TA | 1 |
| Cheng, H | 4 |
| Fan, GL | 3 |
| Fan, JH | 3 |
| Yuan, P | 1 |
| Deng, FA | 1 |
| Qiu, XZ | 1 |
| Yu, XY | 3 |
| Li, SY | 4 |
| Chelakkot, VS | 2 |
| Som, J | 1 |
| Yoshioka, E | 2 |
| Rice, CP | 1 |
| Rutihinda, SG | 1 |
| Hirasawa, K | 2 |
| Ma, W | 1 |
| Sha, SN | 1 |
| Chen, PL | 1 |
| Yu, M | 1 |
| Chen, JJ | 1 |
| Huang, CB | 1 |
| Yu, B | 1 |
| Liu, Y | 2 |
| Liu, LH | 1 |
| Yu, ZQ | 1 |
| Zeng, Z | 1 |
| Huang, Z | 1 |
| Sun, Y | 1 |
| Huang, Y | 1 |
| Ye, J | 1 |
| Yang, H | 1 |
| Yang, C | 1 |
| Zhao, C | 1 |
| Jibin, K | 1 |
| Prasad, JS | 1 |
| Saranya, G | 1 |
| Shenoy, SJ | 1 |
| Maiti, KK | 1 |
| Jayasree, RS | 1 |
| Ren, SZ | 1 |
| Wang, B | 1 |
| Zhu, XH | 1 |
| Zhu, D | 1 |
| Liu, M | 1 |
| Li, SK | 1 |
| Yang, YS | 1 |
| Wang, ZC | 1 |
| Zhu, HL | 1 |
| Xu, P | 1 |
| Xia, Y | 1 |
| Wang, Y | 1 |
| Qi, Y | 1 |
| Qi, C | 1 |
| He, Y | 1 |
| Chang, J | 1 |
| Lai, HW | 2 |
| Nakayama, T | 1 |
| Ogura, SI | 2 |
| Zhang, Z | 1 |
| Li, A | 1 |
| Min, X | 1 |
| Zhang, Q | 1 |
| Yang, J | 1 |
| Chen, G | 1 |
| Zou, M | 1 |
| Sun, W | 1 |
| Cheng, G | 1 |
| Kirino, I | 1 |
| Fujita, K | 1 |
| Sakanoue, K | 1 |
| Sugita, R | 1 |
| Yamagishi, K | 1 |
| Takeoka, S | 1 |
| Fujie, T | 1 |
| Uemoto, S | 1 |
| Morimoto, Y | 1 |
| Liu, K | 1 |
| Saha, S | 1 |
| Xu, D | 1 |
| Licursi, M | 1 |
| Dorward, A | 1 |
| Takahashi, K | 1 |
| Nakajima, M | 1 |
| Tanaka, T | 3 |
| Huo, M | 1 |
| Qian, X | 1 |
| Ding, L | 1 |
| Yu, L | 1 |
| Feng, W | 1 |
| Cui, X | 2 |
| Chen, Y | 1 |
| Xia, J | 1 |
| Qian, M | 1 |
| Bao, Y | 1 |
| Wang, J | 1 |
| Jia, HR | 2 |
| Jiang, YW | 1 |
| Zhu, YX | 2 |
| Li, YH | 1 |
| Wang, HY | 1 |
| Han, X | 1 |
| Yu, ZW | 1 |
| Gu, N | 1 |
| Liu, P | 1 |
| Chen, Z | 1 |
| Wu, FG | 2 |
| Herceg, V | 1 |
| Allémann, E | 1 |
| Babič, A | 1 |
| Sengar, P | 1 |
| Juárez, P | 1 |
| Verdugo-Meza, A | 1 |
| Arellano, DL | 1 |
| Jain, A | 1 |
| Chauhan, K | 1 |
| Hirata, GA | 1 |
| Fournier, PGJ | 1 |
| Zheng, DW | 1 |
| Fan, JX | 1 |
| Liu, XH | 1 |
| Dong, X | 1 |
| Pan, P | 1 |
| Xu, L | 1 |
| Zhang, XZ | 4 |
| Xu, KF | 1 |
| Liu, X | 1 |
| Landes, R | 1 |
| Illanes, A | 1 |
| Goeppner, D | 1 |
| Gollnick, H | 1 |
| Friebe, M | 1 |
| Zheng, RR | 2 |
| Zhao, LP | 2 |
| Jiang, XY | 1 |
| Yang, B | 1 |
| Knipps, J | 1 |
| Fischer, I | 1 |
| Neumann, LM | 1 |
| Rapp, M | 1 |
| Dibué-Adjei, M | 1 |
| Freiin von Saß, C | 1 |
| Placke, JM | 1 |
| Mijderwijk, HJ | 1 |
| Steiger, HJ | 1 |
| Sabel, M | 1 |
| Cornelius, JF | 1 |
| Kamp, MA | 1 |
| Fales, AM | 1 |
| Yuan, H | 1 |
| Vo-Dinh, T | 1 |
| Anand, S | 1 |
| Hasan, T | 1 |
| Maytin, EV | 1 |
| Teng, IT | 1 |
| Chang, YJ | 1 |
| Wang, LS | 1 |
| Lu, HY | 1 |
| Wu, LC | 1 |
| Yang, CM | 1 |
| Chiu, CC | 1 |
| Yang, CH | 1 |
| Hsu, SL | 1 |
| Ho, JA | 1 |
| Suzuki, C | 2 |
| Kato, K | 2 |
| Tsuji, AB | 2 |
| Kikuchi, T | 2 |
| Zhang, MR | 2 |
| Arano, Y | 2 |
| Saga, T | 2 |
| Choe, SW | 1 |
| Terman, DS | 1 |
| Rivers, AE | 1 |
| Rivera, J | 1 |
| Lottenberg, R | 1 |
| Sorg, BS | 1 |
| Xie, H | 1 |
| Xie, Z | 1 |
| Mousavi, M | 1 |
| Bendsoe, N | 1 |
| Brydegaard, M | 1 |
| Axelsson, J | 1 |
| Andersson-Engels, S | 1 |
| Ho, CJ | 1 |
| Balasundaram, G | 1 |
| Driessen, W | 1 |
| McLaren, R | 1 |
| Wong, CL | 1 |
| Dinish, US | 1 |
| Attia, AB | 1 |
| Ntziachristos, V | 1 |
| Olivo, M | 1 |
| Blázquez-Castro, A | 1 |
| Breitenbach, T | 1 |
| Ogilby, PR | 1 |
| Sudo, H | 1 |
| Okada, M | 1 |
| Sugyo, A | 1 |
| Ren, J | 1 |
| Venugopalan, J | 1 |
| Xu, J | 1 |
| Kairdolf, B | 1 |
| Durfee, R | 1 |
| Wang, MD | 1 |
| Han, K | 1 |
| Wang, SB | 1 |
| Zhu, JY | 1 |
| Yang, X | 1 |
| Palasuberniam, P | 1 |
| Kraus, D | 1 |
| Chen, B | 1 |
| Tachikawa, S | 1 |
| Sato, S | 1 |
| Kaneda, Y | 1 |
| Nakamura, H | 1 |
| Fujino, M | 1 |
| Nishio, Y | 1 |
| Ito, H | 1 |
| Li, XK | 1 |
| Honda, N | 1 |
| Kariyama, Y | 1 |
| Ishii, T | 1 |
| Kitajima, Y | 1 |
| Ishizuka, M | 1 |
| Fan, Z | 1 |
| Wei, D | 1 |
| Liu, W | 1 |
| Li, B | 1 |
| He, H | 1 |
| Ye, H | 1 |
| Zhu, N | 1 |
| Wei, X | 1 |
| Lopez, N | 1 |
| Mulet, R | 1 |
| Rodríguez, R | 1 |
| Xie, BR | 1 |
| Song, LL | 1 |
| Zhuo, RX | 1 |
| Zhu, L | 1 |
| Chen, JF | 1 |
| Dai, L | 1 |
| Zhang, N | 1 |
| Zhao, F | 1 |
| Zou, Q | 1 |
| Ma, G | 1 |
| Yan, X | 1 |
| Girotti, AW | 1 |
| Fahey, JM | 1 |
| Korytowski, W | 1 |
| Zawacka-Pankau, J | 2 |
| Krachulec, J | 1 |
| Grulkowski, I | 1 |
| Bielawski, KP | 1 |
| Selivanova, G | 1 |
| Hagiya, Y | 1 |
| Adachi, T | 1 |
| Ogura, S | 1 |
| An, R | 1 |
| Tamura, A | 1 |
| Nakagawa, H | 1 |
| Okura, I | 1 |
| Mochizuki, T | 1 |
| Ishikawa, T | 1 |
| Ferens, B | 1 |
| Thienot, E | 1 |
| Germain, M | 1 |
| Piejos, K | 1 |
| Simon, V | 1 |
| Darmon, A | 1 |
| Marill, J | 1 |
| Borghi, E | 1 |
| Levy, L | 1 |
| Hochepied, JF | 1 |
| Pottier, A | 1 |
| Koo, H | 1 |
| Lee, H | 1 |
| Lee, S | 1 |
| Min, KH | 1 |
| Kim, MS | 1 |
| Lee, DS | 1 |
| Choi, Y | 1 |
| Kwon, IC | 1 |
| Kim, K | 1 |
| Jeong, SY | 1 |
| Golab, J | 1 |
| Korbelik, M | 1 |
| Russell, D | 1 |
| Leblond, F | 1 |
| Ovanesyan, Z | 1 |
| Davis, SC | 1 |
| Valdés, PA | 1 |
| Kim, A | 1 |
| Hartov, A | 1 |
| Wilson, BC | 1 |
| Pogue, BW | 2 |
| Paulsen, KD | 1 |
| Roberts, DW | 1 |
| Sazgarnia, A | 1 |
| Shanei, A | 1 |
| Eshghi, H | 1 |
| Hassanzadeh-Khayyat, M | 1 |
| Esmaily, H | 1 |
| Shanei, MM | 1 |
| Cunderlíková, B | 1 |
| Peng, Q | 3 |
| Mateasík, A | 1 |
| Wu, SM | 1 |
| Ren, QG | 1 |
| Zhou, MO | 1 |
| Wei, Y | 1 |
| Chen, JY | 1 |
| Collaud, S | 1 |
| Juzeniene, A | 2 |
| Moan, J | 4 |
| Uzdensky, AB | 1 |
| Kolpakova, E | 1 |
| Hjortland, GO | 1 |
| Juzenas, P | 1 |
| Sabban, F | 1 |
| Collinet, P | 1 |
| Cosson, M | 1 |
| Mordon, S | 1 |
| Fukuda, H | 1 |
| Casas, A | 1 |
| Batlle, A | 1 |
| Silva, JN | 1 |
| Filipe, P | 1 |
| Morlière, P | 1 |
| Mazière, JC | 1 |
| Freitas, JP | 1 |
| Cirne de Castro, JL | 1 |
| Santus, R | 1 |
| Courrol, LC | 1 |
| de Oliveira Silva, FR | 1 |
| Coutinho, EL | 1 |
| Piccoli, MF | 1 |
| Mansano, RD | 1 |
| Vieira Júnior, ND | 1 |
| Schor, N | 1 |
| Bellini, MH | 1 |
| Zhu, DM | 1 |
| Yang, HP | 1 |
| Luo, XS | 1 |
| Shen, ZH | 1 |
| Lu, J | 1 |
| Ni, XW | 1 |
| Vallinayagam, R | 1 |
| Schmitt, F | 1 |
| Barge, J | 1 |
| Wagnieres, G | 1 |
| Wenger, V | 1 |
| Neier, R | 1 |
| Juillerat-Jeanneret, L | 1 |
| Krammer, B | 1 |
| Plaetzer, K | 1 |
| Gaullier, JM | 1 |
| Anholt, H | 1 |
| Selbo, PK | 1 |
| Ma, LW | 1 |
| Warloe, T | 1 |
| Kongshaug, M | 1 |
| Giercksky, KE | 1 |
| Nesland, JM | 1 |
| Marcus, SL | 1 |
| Sobel, RS | 1 |
| Golub, AL | 1 |
| Carroll, RL | 1 |
| Lundahl, S | 1 |
| Shulman, DG | 1 |
| Gibson, SL | 1 |
| Nguyen, ML | 1 |
| Havens, JJ | 1 |
| Barbarin, A | 1 |
| Hilf, R | 1 |
| Fennell, DA | 1 |
| Cotter, FE | 1 |
| Vaucher, L | 1 |
| Marti, A | 1 |
| Etter, AL | 1 |
| Gerber, P | 1 |
| van Den Bergh, H | 1 |
| Jichlinski, P | 1 |
| Kucera, P | 1 |
| O'Hara, JA | 1 |
| Goodwin, IA | 1 |
| Wilmot, CJ | 1 |
| Fournier, GP | 1 |
| Akay, AR | 1 |
| Swartz, H | 1 |
| Mathews-Roth, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for protoporphyrin ix and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
A Recap of Heme Metabolism towards Understanding Protoporphyrin IX Selectivity in Cancer Cells.
Topics: Aminolevulinic Acid; Animals; Heme; Iron; Mammals; Neoplasms; Porphyrins; Protoporphyrins | 2022 |
In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid?
Topics: Amino Acid Transport Systems; Aminolevulinic Acid; Brain Neoplasms; Coproporphyrinogens; Ferrochelat | 2019 |
Key transporters leading to specific protoporphyrin IX accumulation in cancer cell following administration of aminolevulinic acid in photodynamic therapy/diagnosis.
Topics: Aminolevulinic Acid; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Protoporphyrins | 2021 |
Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement.
Topics: Aminolevulinic Acid; Animals; Heme; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; P | 2015 |
5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction.
Topics: Aminolevulinic Acid; Heme; Heme Oxygenase-1; Histocompatibility; Humans; Immunity; Immunologic Facto | 2016 |
Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Humans; Light; Neoplasms; Nitric Oxide; Nitric Oxide Syntha | 2016 |
The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances.
Topics: Apoptosis; Cell Cycle Proteins; Humans; Neoplasms; Nuclear Proteins; Photochemotherapy; Proto-Oncoge | 2008 |
Enlightened protein: Fhit tumor suppressor protein structure and function and its role in the toxicity of protoporphyrin IX-mediated photodynamic reaction.
Topics: Acid Anhydride Hydrolases; Animals; Apoptosis; Dinucleoside Phosphates; Gene Silencing; Humans; Neop | 2009 |
On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation.
Topics: Aminolevulinic Acid; Animals; Hematoporphyrin Photoradiation; Heme; Humans; Molecular Structure; Neo | 2004 |
[Fluorescence imaging technique: diagnostic and therapeutic interest in gynecology].
Topics: Aminolevulinic Acid; Breast Neoplasms; Female; Genital Diseases, Female; Gynecology; Humans; Neoplas | 2004 |
Use of ALA and ALA derivatives for optimizing ALA-based photodynamic therapy: a review of our experience.
Topics: Aminolevulinic Acid; Animals; Esterases; Heme; Humans; Neoplasms; Photochemotherapy; Photosensitizin | 2006 |
Photodynamic therapies: principles and present medical applications.
Topics: Aminolevulinic Acid; Bowen's Disease; Clinical Trials as Topic; Humans; Light; Lipoproteins, LDL; Ma | 2006 |
ALA and its clinical impact, from bench to bedside.
Topics: Aminolevulinic Acid; Dendritic Cells; Fluorescence; Humans; Keratosis; Lymphocytes; Macrophages; Neo | 2008 |
5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.
Topics: Aminolevulinic Acid; Forecasting; Heme; Humans; Neoplasms; Photochemotherapy; Protoporphyrins; Resea | 1997 |
Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status.
Topics: Aminolevulinic Acid; Animals; Endometrium; Female; Gastrointestinal Neoplasms; Humans; Laser Therapy | 1996 |
Controlling the mitochondrial gatekeeper for effective chemotherapy.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; GABA-A Receptor Antagonists; Gene Expression Regulation; Ge | 2000 |
Beta-carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adolescent; Adult; Animals; Bacteria; Bacterial Physiological Phen | 1986 |
65 other studies available for protoporphyrin ix and Neoplasms
| Article | Year |
|---|---|
Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin.
Topics: Aminolevulinic Acid; Carbazoles; Fluorescence; Humans; Light; Neoplasms; Photochemotherapy; Photosen | 2021 |
A Versatile Nanoplatform for Broad-Spectrum Immunotherapy by Reversing the Tumor Microenvironment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Copper; Erythrocyte Membrane; Humans; Immunity; Im | 2021 |
Protoporphyrin IX delayed fluorescence imaging: a modality for hypoxia-based surgical guidance.
Topics: Aminolevulinic Acid; Fluorescence; Humans; Hypoxia; Neoplasms; Oxygen; Photosensitizing Agents; Prot | 2022 |
Protoporphyrin IX-loaded albumin nanoparticles reverse cancer chemoresistance by enhancing intracellular reactive oxygen species.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Ph | 2023 |
Increased fluorescence observation intensity during the photodynamic diagnosis of deeply located tumors by fluorescence photoswitching of protoporphyrin IX.
Topics: Aminolevulinic Acid; Fluorescence; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pr | 2023 |
Enzyme-triggered deshielding of nanoparticles and positive-charge mediated lysosomal escape for chemo/photo-combination therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Liberation; Human | 2019 |
A new GSH-responsive prodrug of 5-aminolevulinic acid for photodiagnosis and photodynamic therapy of tumors.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Glutathione; Humans; Levulinic Acids; Neoplasms; Optical Imag | 2019 |
Proton-dynamic therapy following photosensitiser activation by accelerated protons demonstrated through fluorescence and singlet oxygen production.
Topics: Cell Death; Cell Line, Tumor; Chemoradiotherapy; Fluorescence; Humans; Neoplasms; Perylene; Photosen | 2019 |
Epigenetics-inspired photosensitizer modification for plasma membrane-targeted photodynamic tumor therapy.
Topics: 3T3 Cells; Amino Acids; Animals; Cell Line, Tumor; Cell Membrane; Epigenesis, Genetic; Humans; Mice; | 2019 |
Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Benzimidazoles; Cell Line, Tumor; Female; Humans; Levulinic Acids; Mal | 2019 |
A Cell Membrane-Targeting Self-Delivery Chimeric Peptide for Enhanced Photodynamic Therapy and In Situ Therapeutic Feedback.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Membrane; Female; Fluorescence Resonance Energy Transfer; | 2020 |
Near-infrared light-triggered degradable hyaluronic acid hydrogel for on-demand drug release and combined chemo-photodynamic therapy.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Doxorubicin; Drug Delivery Systems; Drug L | 2020 |
Optically controlled hybrid metamaterial of plasmonic spiky gold inbuilt graphene sheets for bimodal imaging guided multimodal therapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Chitosan; Doxorubicin; Folic Acid; Gold; Gra | 2020 |
Oxygen Self-Sufficient Core-Shell Metal-Organic Framework-Based Smart Nanoplatform for Enhanced Synergistic Chemotherapy and Photodynamic Therapy.
Topics: Animals; Antineoplastic Agents; Catalysis; Cell Hypoxia; Cell Line, Tumor; Doxorubicin; Drug Carrier | 2020 |
The conjugation of targeted therapy and image-guided phototdynamic therapy of cancer in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Fluorescent Dyes; Humans; Mice, Inbred B | 2020 |
An ROS-sensitive tegafur-PpIX-heterodimer-loaded
Topics: Hydrogels; Neoplasms; Photochemotherapy; Protoporphyrins; Reactive Oxygen Species; Tegafur | 2021 |
Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid.
Topics: Administration, Metronomic; Administration, Oral; Aminolevulinic Acid; Animals; Antineoplastic Agent | 2020 |
MEK reduces cancer-specific PpIX accumulation through the RSK-ABCB1 and HIF-1α-FECH axes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Ferrochelatase; Gene Expre | 2020 |
Mass Spectrometric Analysis of the Photobleaching of Protoporphyrin IX Used in Photodynamic Diagnosis and Therapy of Cancer.
Topics: Aminolevulinic Acid; Humans; Mass Spectrometry; Neoplasms; Photobleaching; Photochemotherapy; Photos | 2021 |
Efficiency of aminolevulinic acid (ALA)-photodynamic therapy based on ALA uptake transporters in a cell density-dependent malignancy model.
Topics: Adaptor Proteins, Signal Transducing; Aminolevulinic Acid; Antineoplastic Agents; Biological Transpo | 2021 |
Autophagy blockade synergistically enhances nanosonosensitizer-enabled sonodynamic cancer nanotherapeutics.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Female; Humans; MCF-7 Cells; | 2021 |
Specific light-up pullulan-based nanoparticles with reduction-triggered emission and activatable photoactivity for the imaging and photodynamic killing of cancer cells.
Topics: Animals; Apoptosis; Biological Transport; Cell Survival; Drug Carriers; Drug Liberation; Fluorescenc | 2017 |
Plasma membrane activatable polymeric nanotheranostics with self-enhanced light-triggered photosensitizer cellular influx for photodynamic cancer therapy.
Topics: A549 Cells; Animals; Cell Membrane; Chitosan; Erythrocytes; Female; Hemolysis; Humans; Light; Mice, | 2017 |
Activity of phosphatase-sensitive 5-aminolevulinic acid prodrugs in cancer cell lines.
Topics: A549 Cells; Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Humans; Light; MCF-7 Cells; Micros | 2017 |
Development of a functionalized UV-emitting nanocomposite for the treatment of cancer using indirect photodynamic therapy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Folic Acid; Luminescent Agents; Male; Mice; Nan | 2018 |
A Simply Modified Lymphocyte for Systematic Cancer Therapy.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Humans; Lasers; Levulinic | 2018 |
Plasma membrane-anchorable photosensitizing nanomicelles for lipid raft-responsive and light-controllable intracellular drug delivery.
Topics: A549 Cells; Animals; Cholesterol; Delayed-Action Preparations; Drug Delivery Systems; Female; Humans | 2018 |
A study of concentration changes of Protoporphyrin IX and Coproporphyrin III in mixed samples mimicking conditions inside cancer cells for Photodynamic Therapy.
Topics: Aminolevulinic Acid; Animals; Coproporphyrins; Equipment Design; Fiber Optic Technology; In Vitro Te | 2018 |
Mitochondria and plasma membrane dual-targeted chimeric peptide for single-agent synergistic photodynamic therapy.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Drug Carriers; Drug Delivery Systems; Mice; Mitochondria; | 2019 |
Ratiometric theranostic nanoprobe for pH imaging-guided photodynamic therapy.
Topics: Animals; Cell Line, Tumor; Fluorescence Resonance Energy Transfer; Humans; Hydrogen-Ion Concentratio | 2019 |
Quantification of PpIX-fluorescence of cerebral metastases: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescent Dyes; Foll | 2019 |
Cell-penetrating peptide enhanced intracellular Raman imaging and photodynamic therapy.
Topics: Cell Line, Tumor; Cell-Penetrating Peptides; Humans; Microscopy, Electron, Transmission; Nanoparticl | 2013 |
Mechanism of differentiation-enhanced photodynamic therapy for cancer: upregulation of coproporphyrinogen oxidase by C/EBP transcription factors.
Topics: Animals; Base Sequence; Binding Sites; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Coproporph | 2013 |
Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Carriers; Endocytosis; Fluorescence; Folic Acid; | 2013 |
Synthesis and in vitro cellular uptake of 11C-labeled 5-aminolevulinic acid derivative to estimate the induced cellular accumulation of protoporphyrin IX.
Topics: Aminolevulinic Acid; Binding, Competitive; Carbon Radioisotopes; Cells, Cultured; Chromatography, Hi | 2013 |
Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery.
Topics: Anemia, Sickle Cell; Animals; Cell Line, Tumor; Drug Delivery Systems; Erythrocytes; Female; Fluores | 2013 |
Design and validation of a fiber optic point probe instrument for therapy guidance and monitoring.
Topics: Aminolevulinic Acid; Animals; Calibration; Carcinoma, Squamous Cell; Equipment Design; Fiber Optic T | 2014 |
Multifunctional photosensitizer-based contrast agents for photoacoustic imaging.
Topics: Cell Line, Tumor; Chlorophyllides; Contrast Media; Cyclobutanes; Diagnostic Imaging; Humans; Indoles | 2014 |
Singlet oxygen and ROS in a new light: low-dose subcellular photodynamic treatment enhances proliferation at the single cell level.
Topics: Aminolevulinic Acid; Apoptosis; Cell Proliferation; HeLa Cells; Humans; Lasers; Neoplasms; Photochem | 2014 |
Preclinical characterization of 5-amino-4-oxo-[6-11C]hexanoic acid as an imaging probe to estimate protoporphyrin IX accumulation induced by exogenous aminolevulinic acid.
Topics: Aminocaproates; Aminolevulinic Acid; Animals; Cell Line, Tumor; Humans; Mice; Neoplasm Transplantati | 2014 |
Multi-channel LED light source for fluorescent agent aided minimally invasive surgery.
Topics: Aminolevulinic Acid; Fluorescent Dyes; Humans; Indocyanine Green; Light; Minimally Invasive Surgical | 2014 |
Ratiometric Biosensor for Aggregation-Induced Emission-Guided Precise Photodynamic Therapy.
Topics: Animals; Biosensing Techniques; Cell Line, Tumor; Humans; Matrix Metalloproteinase 2; Mice; Neoplasm | 2015 |
Localization-dependent cell-killing effects of protoporphyrin (PPIX)-lipid micelles and liposomes in photodynamic therapy.
Topics: Cell Line; HeLa Cells; Humans; Liposomes; Micelles; Neoplasms; Phosphatidylcholines; Photochemothera | 2015 |
Optical properties of tumor tissues grown on the chorioallantoic membrane of chicken eggs: tumor model to assay of tumor response to photodynamic therapy.
Topics: Animals; Anisotropy; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Chromatography, High | 2015 |
eEF1A1 binds and enriches protoporphyrin IX in cancer cells in 5-aminolevulinic acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biological Availability; Cell Line; Gene Library; Hep G2 Cells; Humans; Neoplas | 2016 |
Tumor reactive ringlet oxygen approach for Monte Carlo modeling of photodynamic therapy dosimetry.
Topics: Aminolevulinic Acid; Humans; Models, Theoretical; Monte Carlo Method; Neoplasms; Photochemotherapy; | 2016 |
A ratiometric theranostic probe for tumor targeting therapy and self-therapeutic monitoring.
Topics: Animals; Chlorocebus aethiops; COS Cells; Drug Monitoring; Fluorescence Resonance Energy Transfer; N | 2016 |
Liquid Marbles Based on Magnetic Upconversion Nanoparticles as Magnetically and Optically Responsive Miniature Reactors for Photocatalysis and Photodynamic Therapy.
Topics: Catalysis; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Infrared Rays; Lanthanoid Series | 2016 |
Multitriggered Tumor-Responsive Drug Delivery Vehicles Based on Protein and Polypeptide Coassembly for Enhanced Photodynamic Tumor Ablation.
Topics: Animals; Cell Survival; Chlorophyllides; Drug Delivery Systems; Female; HeLa Cells; Humans; MCF-7 Ce | 2016 |
Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy.
Topics: Aminolevulinic Acid; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette T | 2008 |
One pot synthesis of new hybrid versatile nanocarrier exhibiting efficient stability in biological environment for use in photodynamic therapy.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Humans; Mice; Nanoparticles; Neoplasms; Photochemotherapy; | 2010 |
In vivo tumor diagnosis and photodynamic therapy via tumoral pH-responsive polymeric micelles.
Topics: Animals; Drug Carriers; Hydrogen-Ion Concentration; Mice; Micelles; Microscopy, Fluorescence; Neopla | 2010 |
Drug delivery technologies and immunological aspects of photodynamic therapy.
Topics: Aminolevulinic Acid; Drug Carriers; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Photosensit | 2011 |
Analytic expression of fluorescence ratio detection correlates with depth in multi-spectral sub-surface imaging.
Topics: Algorithms; Animals; Diffusion; Fluorescence; Hemoglobins; Image Enhancement; Light; Neoplasms; Phan | 2011 |
Detection of sonoluminescence signals in a gel phantom in the presence of Protoporphyrin IX conjugated to gold nanoparticles.
Topics: Acoustics; Analysis of Variance; Gels; Gold; Luminescent Measurements; Metal Nanoparticles; Molecula | 2013 |
Factors implicated in the assessment of aminolevulinic acid-induced protoporphyrin IX fluorescence.
Topics: Aminolevulinic Acid; Cell Communication; Cell Line, Tumor; Coculture Techniques; Collagen; Flow Cyto | 2013 |
Photodynamic effects of 5-aminolevulinic acid and its hexylester on several cell lines.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Mitochondria; Neopl | 2003 |
Photosensitization with protoporphyrin IX inhibits attachment of cancer cells to a substratum.
Topics: Cadherins; Cell Adhesion; Fluorescent Antibody Technique; Humans; Integrin alphaVbeta3; Light; Neopl | 2004 |
Study of blood porphyrin spectral profile for diagnosis of tumor progression.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Human | 2007 |
[Fluorescence spectrum analysis system for protoporphyrin IX in serum based on wavelet transform].
Topics: Humans; Neoplasms; Plasma; Protoporphyrins; Spectrometry, Fluorescence | 2007 |
Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer.
Topics: Aminolevulinic Acid; Cell Line; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Esterases; | 2008 |
Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture.
Topics: Adenocarcinoma; Aminolevulinic Acid; Animals; Colonic Neoplasms; Cricetinae; Cricetulus; Drug Screen | 1997 |
Relationship of delta-aminolevulinic acid-induced protoporphyrin IX levels to mitochondrial content in neoplastic cells in vitro.
Topics: Aminolevulinic Acid; Animals; Electron Transport Complex IV; Ferrochelatase; Fluorescent Dyes; Human | 1999 |
Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia.
Topics: Aminolevulinic Acid; Animals; Cell Death; Culture Techniques; Humans; Hydrogen-Ion Concentration; Mi | 2001 |
Tumor PO(2) changes during photodynamic therapy depend upon photosensitizer type and time after injection.
Topics: Animals; Electron Spin Resonance Spectroscopy; Light; Mice; Neoplasm Transplantation; Neoplasms; Oxy | 2002 |